SNSW(SH:688117) 智通财经网·2026-02-11 08:26Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), announced its participation in the national centralized procurement process for pharmaceuticals, marking the first nationwide unified continuation procurement for chemical drugs [1] Group 1: Procurement Participation - The company's wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., is involved in the first to eighth batches of the national centralized procurement [1] - This continuation procurement is significant as it represents the first nationwide unified continuation for chemical drugs organized by the state [1] Group 2: Selected Products - The company’s products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch), are among those proposed for selection in this new round of procurement [1] - Additionally, the company has new products proposed for selection, including Thymosin Alpha 1 Injection and Exenatide Injection [1]